HIIT can take your training and performance to the next level. Here’s everything you need to know about this style of ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...

Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.

Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes.

A doctor and honorary researcher at the University of Exeter is leading a campaign to make reusable insulin pens the standard ...

Bernstein initiated coverage of Insulet (PODD) with an Outperform rating and $300 price target Innovation is driving accelerated insulin pump ...

Insulet stock soared out of a buy zone Friday after the insulin pump-maker "continued the beat-and-raise cadence it has seen in 2024." ...

Other companies are looking to administer insulin with needle-free devices, and insulin pumps, which also make therapy more convenient, are already gaining in popularity. Novo Nordisk is investing ...

Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET. Company Participants. Suzanne Foster - Chief Executive Officer Jason Clemens - Chief ...